The anti-proliferative effects of tamoxifen were more pronounced than its ability to activate SXR, but, as both of the tested breast cancer cell lines are estrogen receptor positive, it is likely that some of the observed effects are mediated through an ER-dependent mechanism. The gene discussed is NR1I2; the disease is breast cancer.